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Background: The prevalence of hepatitis C (HCV) is elevated within prison populations, yet diagnosis in prisons
remains low. Dried blood spot testing (DBST) is a simple procedure for the detection of HCV antibodies; its impact
on testing in the prison context is unknown. Methods: We carried out a stepped-wedge cluster-randomized
control trial of DBST for HCV among prisoners within five male prisons and one female prison. Each prison was
a separate cluster. The order in which the intervention (training in use of DBST for HCV testing and logistic
support) was introduced was randomized across clusters. The outcome measure was the HCV testing rate by
prison. Imputation analysis was carried out to account for missing data. Planned and actual intervention times
differed in some prisons; data were thus analysed by intention to treat (ITT) and by observed step times. Results:
There was insufficient evidence of an effect of the intervention on testing rate using either the ITT intervention
time (OR: 0.84; 95% CI: 0.68–1.03; P=0.088) or using the actual intervention time (OR: 0.86; 95% CI: 0.71–1.06;
P=0.153). This was confirmed by the pooled results of five imputed data sets. Conclusions: DBST as a stand-alone
intervention was insufficient to increase HCV diagnosis within the UK prison setting. Factors such as staff training
and allocation of staff time for regular clinics are key to improving service delivery. We demonstrate that prisons
can conduct rigorous studies of new interventions, but data collection can be problematic. Trial registration:
International Standard Randomized Controlled Trial Number Register (ISRCTN number ISRCTN05628482).
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Introduction
The UK prison population contains a high proportion of individualswho report having injected illicit drugs (PWID),1–3 the major risk
factor for hepatitis C (HCV) in the UK. High rates of recidivism
among PWID have also been reported.4 While research suggests a
low incidence of HCV transmission within prison,5 an elevated
prevalence of HCV and hepatitis B (HBV) has been documented2,6–8
and both human immunodeficiency virus (HIV) and HBV outbreaks
reported.9–11 Sentinel diagnostic testing data from across 39 English
prisons identified an anti-HCV positivity rate of 23% in 2008.12
Uptake of testing for HCV is a Department of Health prison health
performance and quality indicator for English prisons13 although this
does not apply to Welsh prisons. A recent national survey indicated
that the majority of English prisons offer venous testing, with only
10% offering dried blood spot testing (DBST).14 Before this study,
there was no routine testing for HCV (venepuncture or DBST) taking
place within Welsh prisons outwith that offered by the visiting genito-
urinary medicine (GUM) services and General Practitioners (GPs).
Two prison-based studies of HCV testing have reported low
uptake.8,15 Qualitative research has identified barriers to HCV
testing in prison such as concerns around confidentiality as well as
a lack of proactive approaches to encourage testing.16 A review of
HCV and HBV testing across English prisons between 2005 and 2008
identified that although hepatitis testing had increased only a small
proportion (2.4%) of the prison population underwent testing.12
HCV treatment is cost-effective,17,18 and modelling research has
suggested that case finding in prisons could be cost-effective.19–21
A cost-utility analysis of screening of all prisons suggested that
screening was not cost-effective; the findings, however, were
subject to uncertainty and sensitive to estimates of disease pro-
gression.21 The recent public health guidance on promoting and
offering testing for HCV published by The National Institute for
Health and Care Excellence (NICE) recommends that ‘Prison
services should have access to dried blood spot testing for
hepatitis B and C for people for whom venous access is difficult’.
This article presents the results of a stepped-wedge cluster-
randomized control trial (RCT) conducted between March 2011
and September 2012 to determine the impact of DBST on the
uptake of HCV testing in prisons. This trial design is suitable in
this context because, in line with the NICE guidelines,20 the
intention is for all prisons to have access to the intervention. The
stepped-wedge design randomizes the order of the intervention
introduction to prisons. DBST is a safe and simple procedure for
the detection of HCV antibodies.22 An initial pilot within substance
misuse services in North Wales was associated with an increase in
testing.23 Only one trial of DBST to date demonstrated feasibility in
the prison context but was not powered to determine effectiveness.24
Methods
Trial design and participants
We used a stepped wedge cluster RCT design with the intervention
being randomized by start date to five UK prisons. Prisons were
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allocated at random to each of five 1-month steps (Supplementary
figure S1). Each prison was a distinct cluster. Four of the five prisons
had never previously offered routine HCV testing. A 1-month
control period preceded the introduction of the first prison.
Follow-up time was increased to 18 months as it became apparent
that prison-based contextual issues were influencing the ability of
prisons to take part. The study design is indicated in the
Supplementary figure S2; in three of five prisons the intervention
was not introduced in the intended month. The five prisons
recruited were all the prisons in Wales and a prison in England
that receives Welsh female prisoners.
Randomization
Randomization was carried out by the North Wales Organization for
Randomized Trials in Health. The study facilitator (within Public
Health Wales) was informed of the identity of the next prison for the
intervention 2 months before the intended start date. Agreement to
take part was obtained from prison health-care staff.
The intervention
The intervention was the offer of DBST for HCV to prisoners. The
DBST also tested for HBV and HIV infection. DBST was given to
each prison alongside a training package. Prison nurses underwent
training on blood borne virus testing including a description of
HCV, HBV and HIV; transmission risks, treatments available;
prevalence of blood borne viruses; pre- and post-test discussion;
obtaining consent; and record-keeping. Care pathways were drawn
up for each prison to ensure anti-HCV positive patients could be
followed up to confirm active HCV infection and where diagnosis
was confirmed, referred into specialist treatment services. The study
was conducted within the context of the Welsh Government’s ‘Blood
Borne Viral Hepatitis Action Plan for Wales 2010–15’,25 and
alongside a delivery plan for liver health care in Welsh prisons.26
Primary research question
Does the introduction of DBST increase the uptake of testing for
HCV infection in UK prisons?
Primary outcome
Increase in HCV antibody testing rate in prisons following intro-
duction of DBST.
Data collection and data quality
Data on the number of individuals tested within each calendar
month were collected from a range of sources; we used
imputation to take account of missing monthly values. Data
sources are summarized in table 1. Data on new receptions to the
prisons were obtained from prisons; there were 2 months for one
prison where these data were not available. There were also 2 months
with missing testing data from the same prison.
These varied data sources required manual cleaning to arrive at
monthly figures on total testing (venepuncture and DBS combined);
we are aware that the manual cleaning and varied data sources are
likely to have introduced sources of error. Manual cleaning was
attempted to identify duplicate tests on the same individual, for
Table 1 Data sources for the five prisons
Prison DBST data Venepuncture data GUM data Comment
1 From testing laboratory
(no tests identified)
From laboratory systems Assumption that GUM data captured
within laboratory data
Venepuncture data were de-duplicated to
give one record per individual
2 From testing laboratory Directly from GUM service Manual matching did not identify any
venepuncture samples thought to be
follow-up of positive DBS (all DBS
negative)
3 From testing laboratory Data from laboratory
systems
Directly from the GUM service Venepuncture data were de-duplicated to
give one record per individual. Manual
matching was required to remove vene-
puncture samples thought to be follow-up
of positive DBS (two removed)
4 From testing laboratory
was de-duplicated and
presented by month
received and cross-
checked with prison
data, the final month
included samples
tested in last month
of study period but
received in the
following month
From laboratory systems GUM testing was included in total
venepuncture figures
Required consideration of data from two
different laboratories and the prison.
Venepuncture testing was carried out in
two different laboratories. After manual
matching it was apparent that diagnostic
testing was carried out by laboratory A,
while laboratory B carried out confirma-
tory tests and test validation venepunc-
ture; this latter data were not included.
Possible follow-up testing in laboratory A
may have been missed. Venepuncture
data from laboratory A was de-duplicated
5 From prison Data were potentially
available from both
prison and from
laboratory diagnostic
records; however,
owing to uncertainty
with quality of
laboratory data and
difficulties in distin-
guishing GUM from
non-GUM samples in
laboratory records we
relied on prison-based
reports throughout.
Included within (but not distin-
guished within) prison data
It was not possible to determine if any
positive DBS were followed up by vene-
puncture (numbers small).
One month had missing DBST data.
One month had missing GUM data.
Data were missing for the first 4 months of
non-GUM venepuncture testing; these
were assumed to be zero based on
anecdotal knowledge of the prison
health-care system.
New reception data were not available for
2 months.
Prison data were assumed to contain no
duplicates.
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example, when a confirmatory venepuncture sample was taken to
confirm a positive DBST, or when more than one venepuncture test
was carried out (table 1), this may not have captured all follow-up
tests. De-duplication used a laboratory number allocated to the
patient; it is possible that individuals received more than one
number on repeat testing, leading to the inclusion of some repeat
tests. We were not able to determine if any duplicate testing
occurred within GUM testing or whether prisoners tested in the
confidential GUM service were subsequently tested elsewhere
within the prison health service. In one prison, missing data for 4
months on venepuncture outwith GUM testing were estimated as
zero based on anecdotal knowledge.
Sample size
The sample size of five prisons was determined using the method of
Hussey and Hughes,27 one to each 1-month step. A throughput of
150 per prison was assumed. Based on the trial of Hickman et al.,24
we assumed a current testing rate of 8%, estimated a coefficient of
variation of 0.8 and aimed to demonstrate a doubling of testing to
16% post-intervention, with an excess of 95% power to detect such a
change, given a 1% significance level.
Statistical methods
The graphic view of data in each prison uses the locally weighted
scatter plot smoothing (LOESS) curve.28 Because the data were
collected on the number of tests and the number of new
receptions per month, the generalized linear model (GLM)29,30
with binomial distribution was adopted. There were differences in
the size of the prisons, and to accommodate differing test rates the
analyses treated the prison as a fixed effect in GLM as well as its
interaction effects with other covariates/factors. Missing values on
the number of tests per month and the number of receptions were
imputed using multivariate imputation by chained equations
(MICE)31 and implemented by the R package ‘mice 2.9’.32
Setting
The study took place across one female closed local prison, two male
local adult remand prisons, one male convicted prison (adults and
young offenders) and one male open prison. The female prison
carried out routine HCV testing services (venepuncture) before
the study. All prisons offered health care facilities, with four of
five providing 24-hour onsite health-care cover. Total capacity for
the five prisons in the study was 3600.
Inclusion and exclusion criteria
All prisoners able to give informed consent for diagnostic testing
were eligible to be considered for testing. Testing for HCV took place
following a pre-test discussion. In some instances, HCV testing was
postponed because of prioritizing other physical or mental health
issues.
Ethical approvals
The research was an evaluation of an intervention that was both
supported by NICE guidance and the Wales Blood Borne Viral
Hepatitis Action Plan. However, we were aware the study design
potentially altered the pace at which the intervention was
introduced, and the research involved recipients of health services
within prisons and involved prisoners who are a vulnerable
population. We thus took care to ensure the work was acceptable
to the Research Ethics Committee for Wales, the National Offender
Management System (NOMS) and the Ministry of Justice. These
governing bodies took the view that the proposed work did not
require further approvals; however, one of the authors attended an
ethics committee meeting in which the committee reviewed the
study on a voluntary basis; the members present agreed that had
the study fallen within their remit it would have been given a
favourable opinion (REC reference 10/MRE09/23).
Patient consent
Patient consent was not relevant within the context of the trial; the
intervention was rolled out as part of a wider response to diagno-
sis within the Blood Borne Viral Hepatitis Action Plan for Wales
2010–15.
The trial was registered with the International Standard
Randomized Controlled Trial Number Register (ISRCTN number
ISRCTN05628482) and funded by the Welsh Government.
Results
In three of five prisons, the planned date for introducing each inter-
vention (the ‘step’ of the stepped wedge) and the actual date at
which training in using DBST took place did not match that
indicated in the study design (Supplementary figure S2). The inter-
vention in the fourth prison was delayed until after the trial period.
Fluctuations in prison health-care staffing levels as well as staff avail-
ability for training were factors in these delays. The prison charac-
teristics in terms of monthly new receptions, venepuncture tests,
DBST and total tests are summarized in table 2. A summary of
variables by prisons shown stratified by control (pre-intervention)
and post-intervention periods is shown in Supplementary table S1.
No harms were identified.
Data are shown by intention to treat (ITT) and by actual inter-
vention. In the former intervention, date is set as planned and in the
latter, the date it occurred. This date influences the categorization of
months into control or intervention groups. The HCV test rate (the
ratio of the total number of tests over the number of new receptions)
is shown for each prison under both ‘intention to teat’ and ‘actual’
analysis.
The change of HCV test rate over time within each prison and
then over the five prisons together is shown in figure 1. The control
month for Prison 1 was March 2011 where the number of venepunc-
ture tests was missing. There was an increasing test rate from January
2012. For Prison 2, there was a noticeable decrease in the rate in the
control months, and an overall decreasing trend throughout the
intervention months. For Prison 3, the test rate was stationary
until February 2012, followed by a sharp increase during March
and June 2012 and then fell down to around 5%. For Prison 4,
the HCV test rate was near zero but with a sudden increase
during the last 2 months. For Prison 5, the test rate increased
slightly at the beginning of the intervention and then decreased
gradually and picked up during the last 2 months. Pulling all five
prisons together revealed a higher HCV test rate during the inter-
vention months. Although Prison 4 did not receive the intervention,
it was included in the GLM analysis to reflect the seasonal effect on
the test rate.
Table 3 shows that there was insufficient evidence of an effect of
the intervention on testing rate using either the ITT intervention
time (OR: 0.84; 95% CI: 0.68–1.03; P= 0.088) or using the actual
intervention time (OR: 0.86; 95% CI: 0.71–1.06; P= 0.153) after
adjusting the prison variation and time effect based on the
original data. This was confirmed by the pooled results of five
imputed data sets.
Discussion
There was insufficient evidence of an effect of the intervention on
testing rate using either the ITT intervention time or the actual
intervention time. This was confirmed by the pooled results of five
imputed data sets. Despite the evidence in non-controlled
community-based settings that DBS increases testing,23 it would
appear that the intervention alone is insufficient to significantly
increase diagnosis within the UK prison setting. This result is
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influenced by the fact that only one of five prisons was consistently
offering HCV testing before the study. For the remaining four of five
prisons, DBST was introduced to an environment where routine
HCV testing services had yet to be established. Implementing
DBST in these prisons involved significant training for staff.
Therefore, the study results do not show the long-term impact of
the DBST intervention, but instead provide a picture of the initial
introduction of a new service. Our approach to capturing contextual
factors was anecdotal rather than structured; a more in-depth
process evaluation would have strengthened data interpretation.33
We have demonstrated that it is feasible to carry out a RCT in the
prison setting where randomization is of prisons rather than of in-
dividuals; this is to the best of our knowledge the first time this has
been done within the UK prison system. The methodological
approach used in this study is suitable for the evaluation of
complex interventions34 and reduces the potential confounding
likely to be encountered in a non-controlled trial before and after
study. Published RCTs of health-care interventions carried out
within UK prisons are few.35–37
Stepped wedge designs are ideal for a situation like this where there
has been a policy decision to implement an intervention despite a
potential lack of evidence of efficacy. Alternate designs, the individu-
ally randomized and the cluster-randomized trial designs, deny half
the study population access to a mandated intervention. The stepped
wedge design is a pragmatic, yet rigorous, method of evaluating
public health interventions as they are rolled out. This intervention
is accepted by NICE and being implemented. We took the oppor-
tunity to use that roll out to rigorously evaluate, at little cost, DBST,
which would not have otherwise been possible.
As all prisons are supplying both control and intervention subjects
half the number of prisons (and therefore half the logistical
problems) are needed to supply the same number of individuals as
a cluster randomized trial under the same power conditions. The
study, however, will therefore take longer than a conventional cluster
RCT. This too has its advantages, especially in a situation where an
intervention proves difficult to implement. The prolonged time
allows a better longitudinal view on implementation, and in this
case we were able to observe whether there was a drop off of inter-
vention uptake after initial enthusiasm, or a steadily improving take
up. Any shorter study, such as a cluster RCT, would have not had
that opportunity.
The methodological framework imposed on the collection of
data revealed both problems and weaknesses in data collection
within the UK prison settings and highlighted potential
contextual factors that may impact on intervention success.
Further study is required to better elucidate these contextual
factors and should ideally be built into the study design from
the outset. Given common challenges facing the UK prison
system, we assume that these findings are likely to be
generalizable to other settings.
Two controlled trials in the USA have examined the impact of the
timing of the offer of HIV testing on uptake within jails,38,39 and
these suggest that the timing of offer of tests and how they fit in with
prison reception process may be important. A recent cost-utility
analysis indicated that increasing HCV testing in prisons is cost-
effective given minimal continuity of care with community and
uptake of HCV treatment.40
The anti-HCV positivity rate of 13.3% reported from the
laboratory data management system reinforces previous evidence
that prisoners are at high risk of HCV infection.
Study limitations
Data on testing rates were collected from a range of sources and at
times identification of samples from prison inmates was
problematic; this may have introduced errors. Certain data points
were missing; despite imputation this weakened the validity of the
study findings. Manual cleaning of data to remove duplicates was
required; in addition, to avoid double counting, we manually
removed venepuncture follow-up tests that resulted from an initial
Table 2 Summary of variables by month across prisons over the study period
Variable Prison 1 Prison 2 Prison 3 Prison 4 Prison 5
New receptions
Nmis 2 0 0 0 0
Monthly mean 167.53 150.68 312.79 45.68 148.58
SD 31.94 14.83 87.68 15.45 26.41
Range 109–208 127–172 166–468 10–66 93–196
Median (Quartiles) 167 (144, 196) 150 (139, 165) 319 (242, 367) 49 (38, 55) 150 (136, 164)
Total 2848 2863 5943 868 2823
Venepuncture
Nmis 1 0 0 0 0
Monthly mean 35.78 25.95 7.79 0.11 11.95
SD 20.71 20.78 3.49 0.32 5.33
Range 5–71 0–83 2–15 0–1 4–24
Median (Quartiles) 31 (23, 53) 21 (12, 32) 7 (6, 10) 0 (0, 0) 12 (8, 15)
Total 644 493 148 2 227
DBS
Nmis 1 0 0 0 0
Monthly mean 0.61 32.95 5.42 1.47 0.00
SD 2.12 27.28 11.44 5.16 0.00
Range 0-9 0-97 0-36 0-22 0-0
Median (Quartiles) 0 (0, 0) 35 (10, 46) 0 (0, 5) 0 (0, 0) 0 (0, 0)
Total 11 626 103 28 0
Total tests
Nmis 2 0 0 0 0
Monthly mean 35.88 58.90 13.21 1.58 11.95
SD 20.68 17.52 13.10 5.14 5.33
Range 5-71 36-105 2-47 0-22 4-24
Median (Quartiles) 29 (22, 56) 54 (48, 68) 7 (6, 16) 0 (0, 0) 12 (8, 15)
Total 610 1119 251 30 227
Nmis is the number of months with missing values.
Monthly mean is the average monthly value over the study period (19 months) for each prison.
Total is the sum over the study period for each prison.
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positive DBST; this process may have introduced errors to the
monthly testing activity counts and was not possible for a small
number of DBST (table 1). We used NOMS data to provide denom-
inator figures for prison activity; this may have introduced an
unknown level of error into the estimates as we are aware that
double counting is possible with this data set; however, this
potential double counting will likely equally affect both control
and intervention time points and therefore not bias any results.
The intention of the study was to offer the test to all new arrivals;
we cannot be sure the extent to which the discretion of prison health
staff, and other circumstantial factors, influenced the offer of the
test.
Conclusions
DBST introduced as an intervention to five UK prisons did not
significantly increase the uptake of testing. In this study we show
that DBST alone is insufficient to increase testing; the intervention is
complex and structural and operational barriers can reduce any
intervention effect and need to be addressed as part of the interven-
tion. Future studies of interventions to improve blood borne virus
diagnosis should consider a longer control period and build in
sufficient follow-up. Procedures for collecting data on prison
inmates need to be planned beforehand, as procedures may vary
between prisons.
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Figure 1 Total test rate over time with fitted LOESS curve for each prison and for all five prisons. (Black circles indicate the control group,
blue crosses indicate the actual intervention group; the grey dashed vertical line indicates the ITT intervention time; LOESS curve is fitted
separately for control and actual intervention groups)
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We recommend that, in line with NICE guidelines, DBST is
offered within prisons; however, to maximize the benefit of this
new technology, this study highlights the importance of a compre-
hensive approach to improving HCV diagnosis. To introduce the
technology alone, without a wider integration of training and
support for staff, without awareness raising among inmates and im-
portantly without the capacity and stability in prison health services
necessary for major service developments would appear to be insuf-
ficient to lead to improvements in case finding. We argue that the
methodology piloted here is suitable for studies addressing this
important question and other rigorous evaluations of public
health interventions within the prison context.
Supplementary data
Supplementary data are available at EURPUB online.
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Key points
 Inmates of the UK prisons have an elevated prevalence of
HCV, yet diagnostic rates remain poor.
 Venepuncture may be problematic for individuals with
compromised venous access, common among people who
inject drugs who are the largest risk group for infection in
prison populations in the Western world.
 DBST is a safe and acceptable means of testing for the
presence of HCV antibody.
 Despite evidence in non-controlled community-based
settings that DBS increases testing, it would appear that
the introduction of DBST alone is insufficient to signifi-
cantly increase testing within the UK prisons.
 The stepped wedge cluster randomized trial is a potentially
valuable methodological approach to evaluate the effective-
ness of specific health-care interventions within prisons.
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